Abstract
BackgroundICIs are a promising class of drugs that have improved the treatment of a broad spectrum of cancers. Biomarkers such as high Tumor Mutation Burden (TMB), high PD-L1 expression, or...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
